Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalyst Pharm Inc (NQ: CPRX )

21.12 -0.03 (-0.14%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharm Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
NASDAQ:CPRX stands out as a growth opportunity that won't break the bank.
Don't overlook CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
Immunome Stock Sees RS Rating Jump To 91
Immunome stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 88 to 91. 
Via Investor's Business Daily
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
PTC Therapeutics Stock Earns RS Rating Upgrade To 83
The Relative Strength (RS) Rating for PTC Therapeutics stock climbed into a new percentile Monday, with a rise from 80 to 83. 
Via Investor's Business Daily
Top 3 Health Care Stocks That May Crash In August
Via Benzinga
The Latest Analyst Ratings For Catalyst Pharmaceuticals
Via Benzinga
A Closer Look at 7 Analyst Recommendations For Catalyst Pharmaceuticals
Via Benzinga
Decoding 8 Analyst Evaluations For Catalyst Pharmaceuticals
Via Benzinga
CPRX Stock Earnings: Catalyst Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
CPRX stock results show that Catalyst Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Top 3 Health Care Stocks You May Want To Dump This Quarter
Via Benzinga
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
On Friday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 82, up from 64 a day earlier. 
Via Investor's Business Daily
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Decoding 7 Analyst Evaluations For Catalyst Pharmaceuticals
Via Benzinga
Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
The Company will Host a Conference Call and Webcast on Thursday, August 8, 2024, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Trading SMID Biotech Stocks In A Volatile Market
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... 
Via Talk Markets
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
2 Incredible Growth Stocks to Buy Hand Over Fist Right Now
These two healthcare stocks may be deeply undervalued. 
Via The Motley Fool
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating
On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79. 
Via Investor's Business Daily
Catalyst's New CEO Has Big Ideas For The Small Biotech
Richard Daly is Catalyst Pharmaceuticals' second CEO, taking over for Patrick McEnany, who retired last year. 
Via Investor's Business Daily
CPRX Stock Earnings: Catalyst Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
CPRX stock results show that Catalyst Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Top 10% Biotech Catalyst Pharma Slips On Mixed First-Quarter
The company doubled Wall Street's earnings views, but sales came in short. 
Via Investor's Business Daily
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
The Company will Host a Conference Call and Webcast on Thursday, May 9, 2024, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
Don’t miss out on these three strong buy biotech stocks that are leaders to add to your portfolio for Q2 this year. 
Via InvestorPlace
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.